{"analyses":[{"ciLowerLimit":"-0.0353","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.0605","estimateComment":"A positive difference between the treatment groups favors the panitumumab group.","groupDescription":"Repeated measures mixed model includes treatment, geographic region, ECOG score, assessment week, and treatment by assessment week interaction as fixed effects, and subjects a random effect. An unstructured covariance matrix is used in the mixed model.","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY_OR_OTHER_LEGACY","paramType":"LS Mean Difference","paramValue":"0.0126"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-0.0806","upperLimit":"0.0123","value":"-0.0341"},{"groupId":"OG001","lowerLimit":"-0.0691","upperLimit":"0.0260","value":"-0.0216"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"150"},{"groupId":"OG001","value":"143"}],"units":"Participants"}],"description":"The EQ-5D is a standardized instrument for use as a generic measure of health outcome. The health state index measures the following 5 health dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension contains 3 levels of response to reflect degree of problems participants have experienced: no problem (1), some problem (2) and extreme problems (3). The health states for each respondent are converted into a single index number using a specified set of weights. Resulting scores can range from 1.0 and -0.594. A higher score indicates a more preferred health status with 1.0 representing perfect health and 0 representing death. Negative scores are possible and represent health states regarded as less preferable than death (0). Repeated measures mixed model includes treatment, geographic region, ECOG score, assessment week, and treatment by assessment week interaction as fixed effects, and participants a random effect.","dispersionType":"95% Confidence Interval","groups":[{"description":"Cetuximab 400 mg/m\\^2 as an initial dose, followed by 250 mg/m\\^2 intravenously (IV) every 7 days.","id":"OG000","title":"Cetuximab"},{"description":"Panitumumab 6 mg/kg IV every 14 days.","id":"OG001","title":"Panitumumab"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"Patient reported outcomes (PRO) analysis set: all participants in the primary analysis set who have a Baseline and at least one follow-up PRO assessment prior to clinical or objective disease progression per RECIST version 1.1. Participants with available data are included.","reportingStatus":"POSTED","timeFrame":"From Study Day 1 through the last day of treatment or disease progression, up to Week 85.","title":"Change From Baseline in EuroQOL 5 Dimension (EQ-5D) Health State Index Score","type":"SECONDARY","unitOfMeasure":"scores on a scale"}